The agreement will see international initiatives to fight the next pandemic, but funding remains the weak link.

The Japanese MHLW has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations for MM.

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio for SSGJ-707.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s Leqembi for early-stage Alzheimer’s disease, ...

The US FDA has approved Incyte’s Zynyz (retifanlimab-dlwr) in conjunction with carboplatin and paclitaxel (platinum-based ...